Clinical Trial Update: Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity [Phase 2]

View source ↗

Summary

Phase 2 trial update exploring afatinib response and resistance in intratumour heterogeneity for non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: University College, London | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED